Sac-TMT and KL-A167 for HR+/HER2- Breast Cancer
Part of Cancer, Skin clinical trials.
This trial is testing a combination of two drugs, Sac-TMT and KL-A167, in people with a certain type of advanced breast cancer (HR+/HER2-) that is PD-L1 positive. It's for those whose cancer has gotten worse after treatment with a CDK4/6 inhibitor and hormone therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have HR-positive, HER2-negative breast cancer that is advanced or has spread.
- Your cancer has gotten worse while on or within 12 months of finishing a CDK4/6 inhibitor plus hormone therapy.
- Your cancer tests positive for PD-L1 (a protein that helps cancer hide from the immune system).
- You have at least one tumor that can be measured on scans, and your overall health is good (able to do daily activities).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two drugs—Sacituzumab Tirumotecan (Sac-TMT) and an immunotherapy called KL-A167—given before surgery to shrink triple-negative breast tumors. It aims to improve outcomes for people with early-stage, high-risk breast cancer who have not yet had any treatment.
This trial tests a combination of two targeted therapies (lorlatinib and sacituzumab tirumotecan) as first treatment for advanced non-small cell lung cancer with an ALK gene change. The goal is to see if the combination works better than current treatments and to use a simple blood test to guide therapy.
This trial tests two new drugs (sacituzumab tirumotecan and pembrolizumab) against standard treatments for a type of advanced breast cancer that is hormone receptor positive and HER2 negative. It's for people whose cancer has worsened despite hormone therapy with a CDK4/6 inhibitor.
This trial tests a combination of two drugs, sacituzumab govitecan (Sac-TMT) and toripalimab, as a first treatment for women with advanced triple-negative breast cancer that tests positive for a protein called PD-L1. The goal is to see if this combination is safe and effective in shrinking or controlling the cancer.
This trial tests a new drug, Sac-TMT, given alone or with an immunotherapy drug (pembrolizumab) for people with advanced triple-negative breast cancer who have not yet received any treatment for advanced disease. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests two drugs together for advanced ovarian, endometrial, or cervical cancer that has a specific genetic feature called MSI-H or dMMR. The goal is to see if this combination can help shrink or control the cancer.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.